Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Retatrutide
Beginner tier: 1 mg, weekly · clinical trials
Also known as: LY3437943, LY-3437943, Triple G
25.0% mean body weight reduction at 80 weeks on 12 mg in TRIUMPH-1, a peer-reviewed Phase 3 trial of 2,339 adults (NEJM 2026). That puts the retatrutide peptide (LY3437943) among the largest mean weight losses reported in an obesity trial so far. No head-to-head trial against tirzepatide or semaglutide exists yet. It works by activating three receptors at once: GLP-1, GIP, and glucagon. The glucagon piece is what separates it from tirzepatide and semaglutide, driving direct hepatic fat oxidation and higher resting energy expenditure. With no FDA approval yet, access means a trial or Lilly's expanded access program. FDA says compounded retatrutide isn't eligible for 503A or 503B (2025 warning letters). GI side effects during titration are real and often intense.
What Is Retatrutide?
25.0% mean body weight lost at 80 weeks on 12 mg in TRIUMPH-1 (n=2,339, NEJM 2026)[9], vs 3.9% on placebo. That peer-reviewed analysis counts everyone randomized, including people who stopped the drug, so it runs lower than on-treatment toplines. The smaller TRIUMPH-4 trial (n=445, December 2025) enrolled adults with obesity and knee osteoarthritis. Its Lilly topline reported 28.7% at 68 weeks and has not been peer-reviewed. No head-to-head trial against tirzepatide or semaglutide exists yet.
The retatrutide peptide (LY3437943, CAS 2381089-83-2) is a 39-amino-acid synthetic lipopeptide developed by Eli Lilly. Known in community forums as reta peptide or Triple G, it activates GLP-1, GIP, and glucagon receptors simultaneously in a single molecule. The GLP-1 component suppresses appetite and slows gastric emptying. GIP improves insulin response and buffers GLP-1 tolerability. Glucagon raises resting energy expenditure and burns liver fat directly. That third receptor is the differentiator; dual agonists like tirzepatide lack it entirely.
Clinicians and researchers tracking the obesity pharmacotherapy space have been watching retatrutide since the Phase 2 readout (Jastreboff et al., NEJM 2023)[1], where 338 adults lost up to 24.2% body weight at 48 weeks on the 12 mg dose. A substudy of that trial in 98 adults with MASLD (Nature Medicine 2024)[2] tracked liver fat. On 12 mg, it fell 82.4% from baseline by week 24. More Phase 3 results landed in 2026. In adults with type 2 diabetes, TRIUMPH-2 (n=1,152) found 18.8% weight loss on 12 mg vs 5.1% on placebo at 80 weeks (Lancet 2026)[13]. TRIUMPH-3, in adults with established cardiovascular disease, reported 22.6% in a Lilly topline (July 2026).
Community interest runs highest among people who plateaued on semaglutide or tirzepatide. The enthusiasm is high; so are the GI side effects during dose escalation. Lilly plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027. Until approval, retatrutide carries no FDA approval and no insurance coverage.
How Retatrutide Works
Three receptors. One molecule. Retatrutide binds GLP-1, GIP, and glucagon receptors simultaneously, making it the only triagonist in late-stage clinical development.
GLP-1 receptor activation suppresses appetite centrally through hypothalamic satiety pathways and slows gastric emptying peripherally. This is the same mechanism behind semaglutide and liraglutide. GIP receptor agonism potentiates glucose-dependent insulin secretion from pancreatic beta cells while improving tolerability of GLP-1 effects on the gut. Tirzepatide uses GLP-1 plus GIP; retatrutide adds a third target.
The glucagon receptor component is what makes this molecule different. Glucagon activation increases resting energy expenditure and promotes hepatic fat oxidation, converting liver triglycerides to ketone bodies. Phase 2a MASLD data [2] confirmed this clinically: 82.4% relative liver fat reduction at 12 mg in 24 weeks. Comparisons with GLP-1 or dual-agonist liver data are cross-trial only.
The triple mechanism produces additive weight loss because each receptor targets a distinct metabolic pathway. Appetite drops. Energy expenditure rises. Liver fat burns off. The result, based on Jastreboff's Phase 2 [1] and TRIUMPH-4 Phase 3 data, is weight loss larger than single or dual agonists produced in their own trials, though no head-to-head trial exists yet.
Retatrutide Benefits
- Retatrutide benefits center on weight loss, liver fat clearance, and broad metabolic improvement driven by its triple-receptor mechanism.
- 25.0% mean body weight reduction at 80 weeks on 12 mg in Phase 3 TRIUMPH-1 (n=2,339, NEJM 2026)[9], vs 3.9% on placebo. Both figures count everyone randomized. TRIUMPH-4 (n=445, 68 weeks) reported 28.7% on 12 mg in a 2025 Lilly topline that has not been peer-reviewed.
- Liver fat reduced by 82.4% at 12 mg in 24 weeks (Phase 2a MASLD trial, n=98)[2]. 79 to 86% of participants reached normal liver fat levels below 5%.
- Community reports put appetite suppression onset at 3 to 5 days, and some users describe it as faster than on semaglutide; no head-to-head trial has tested that. Food noise and cravings described as virtually eliminated at therapeutic doses.
- Metabolic markers improve across the board: non-HDL cholesterol, triglycerides, hsCRP and systolic blood pressure all fell in TRIUMPH-4, with systolic pressure down 14.0 mmHg on 12 mg (Lilly topline, December 2025).
- Once-weekly subcutaneous injection. The C20 fatty-diacid side chain provides albumin binding that extends the half-life to approximately 6 days.
- Renewed weight loss reported by community users who had plateaued on tirzepatide or semaglutide, consistent with the additional glucagon receptor activity driving energy expenditure beyond what dual agonists achieve.
Retatrutide: Science vs Community Consensus
TRIUMPH-1 (NEJM 2026, n=2,339) reported 25.0% mean body weight reduction at 80 weeks on 12 mg, counting everyone randomized.
Read the evidence (key study, limitations)
TRIUMPH-4's Lilly topline (Dec 2025) gave 28.7% at 68 weeks under the efficacy estimand, or 23.7% counting everyone. Phase 2 demonstrated 24.2% at 48 weeks [1]. MASLD Phase 2a showed up to 82.4% liver fat reduction at 24 weeks [2]. Evidence base is strong across Phase 2 and four Phase 3 obesity readouts (TRIUMPH-1 to -4); TRIUMPH-1 and TRIUMPH-2 are now peer-reviewed.
TRIUMPH-4 Phase 3 (Lilly press release, Dec 11 2025): n=445 adults with obesity + knee OA; 12 mg = −28.7% body weight, 9 mg = −26.4% at 68 weeks. Phase 2 obesity (Jastreboff et al., NEJM 2023, PMID 37366315): n=338, −24.2% at 48 wk (12 mg). MASLD Phase 2a (Nature Medicine 2024, PMID 38858523): n=98, −82.4% relative liver fat at 24 wk (12 mg).
Not yet FDA approved; Lilly plans a BLA submission in Q1 2027. Phase 3 readouts so far: TRIUMPH-4 (Dec 2025); TRIUMPH-1 (NEJM 2026, PMID 42814954, n=2,339: 17.6%, 23.7%, and 25.0% at 80 weeks on 4, 9, and 12 mg vs 3.9% on placebo under the treatment-regimen estimand; Lilly's May 2026 topline gave 19.0%, 25.9%, and 28.3% vs 2.2% under the efficacy estimand, which assumes everyone stayed on drug; a Lilly-reported extension reached 30.3% at 104 weeks on 12 mg in adults with BMI 35 or higher); TRIUMPH-2 (Lancet 2026, PMID 42810372, n=1,152: 11.9%, 16.8%, and 18.8% vs 5.1% at 80 weeks, treatment-regimen estimand); TRIUMPH-3 (Lilly topline, Jul 23 2026, 22.6% at 80 weeks); TRANSCEND-T2D-1 in type 2 diabetes (Lancet 2026, PMID 42250575). TRIUMPH-3 and TRIUMPH-4 are still Lilly toplines, not yet peer-reviewed. No cardiovascular outcomes trial data yet. Dose-dependent resting heart rate increase observed in Phase 2, peaking at week 24; Phase 3 heart rate data are not yet published. Long-term data beyond 104 weeks absent. Weight regain on discontinuation expected (GLP-1 class effect).
Referred to as "Godzilla" and "Triple G" in weight-loss communities.
Read the reports (what users report 6, common issues 6)
High enthusiasm from users who plateaued on semaglutide or tirzepatide. Compounded versions widely used despite investigational status. Users report stronger and faster appetite suppression than on class peers; no head-to-head trial has tested it. GI side effects and heart rate elevations are the primary complaints.
- Appetite suppression onset within 3–5 days, described as faster than on semaglutide (no head-to-head trial)
- 1.5–2.5 lbs/week weight loss at 4–8 mg without active caloric tracking
- Food noise virtually eliminated; cravings more suppressed than on GLP-1 monotherapy
- Renewed weight loss in users who plateaued on tirzepatide or semaglutide
- Liver fat visibly improving on imaging (reported by users with prior MASLD diagnosis)
- Alcohol cravings reduced (consistent GLP-1 class observation)
- Nausea and vomiting intense at doses ≥8 mg if titration is rushed: more severe than comparable GLP-1 agents
- Elevated resting heart rate / palpitations: a notable adverse effect at therapeutic doses, some users reduced dose
- Functional fatigue ("wipeout") the day after injection at high doses
- Product quality uncertainty from compounded and grey-market sources
- No insurance coverage; high out-of-pocket cost ($200–650/month)
- Legal status worries: no FDA approval, and an FDA warning letter (September 9, 2025) says compounded retatrutide is not eligible for the 503A/503B exemptions
Community titration closely mirrors Phase 2 trial design. Efficacy expectations align with clinical data. Community awareness of heart rate and GI side effects matches Phase 2 safety signals. Community caution about product quality is appropriate given non-approved status.
Retatrutide Dosage Guide
Going up in steps? Track the dose ladder
Phase 3 TRIUMPH trials start retatrutide at 2 mg weekly and step up every 4 weeks. Many community users start lower, at 1 mg (the dose of the fixed low-dose arm in Phase 2), regardless of prior GLP-1 experience. The triple-receptor mechanism means your gut is adapting to three agonists at once. Even users who tolerated tirzepatide at high doses report rougher GI onboarding with retatrutide.
Reconstitution math for common vial sizes: a 10 mg vial with 2 mL bacteriostatic water gives you 5 mg/mL. At that concentration, 1 mg equals 0.2 mL, which is 20 units on a standard 100-unit insulin syringe. A 4 mg dose would be 80 units. For the 12 mg maintenance dose, you'll want a 15 mg vial with 2 mL BAC water (7.5 mg/mL); 12 mg then equals 1.6 mL or 160 units. At 160 units, consider splitting across two injection sites to reduce volume discomfort.
Track your resting heart rate from day one. The glucagon component raises energy expenditure, and HR is the clearest early signal of dose-dependent cardiovascular stress. If your resting pulse sits above 90 bpm for more than a week, hold the current dose before escalating.
Evening injections let you sleep through peak nausea, which typically hits 4 to 8 hours post-injection.
Retatrutide is not FDA approved and lacks long-term safety data beyond 104 weeks. Cycling decisions are primarily driven by the need for periodic safety evaluation (heart rate, metabolic markers, liver function) rather than established receptor desensitization. Weight regain on discontinuation is a consistent GLP-1 class effect: continuous use appears necessary for sustained weight maintenance, consistent with its positioning as a chronic disease therapy.
- Persistent resting heart rate >100 bpm despite holding at the current dose
- Progressive GI symptom worsening after extended period at a stable dose (possible sensitization)
- Planned surgery or procedure requiring temporary discontinuation per physician guidance
- Goal weight reached: transition to minimum effective maintenance dose discussion with prescriber
Or use the universal Peptide Calculator for any peptide.
Retatrutide Protocols by Goal
Expected: 24.2% mean body weight loss at 48 weeks (Phase 2, 12 mg); 25.0% at 80 weeks counting everyone randomized (Phase 3 TRIUMPH-1, 12 mg). Up to 82.4% liver fat reduction in MASLD subgroup (Phase 2a, 12 mg).
Monitor: Check resting heart rate weekly during titration. Lipid panel and liver enzymes at baseline and 12 weeks. Blood glucose monitoring if diabetic or pre-diabetic.
How to Inject Retatrutide
- 1Step 1
Clean the top of your lyophilized retatrutide vial with an alcohol swab. Draw 2 mL of bacteriostatic water into a syringe and inject it slowly down the inner wall of the vial. Do not shake. Swirl gently until the powder dissolves completely.
- 2Calculate your syringe units
With a 10 mg vial and 2 mL BAC water, your concentration is 5 mg/mL. For a 1 mg dose, draw 20 units on a 100-unit insulin syringe. For 2 mg, draw 40 units. For 4 mg, draw 80 units. For 8 mg, draw 160 units (or use a 15 mg vial at 7.5 mg/mL for higher doses; 8 mg then equals approximately 107 units).
- 3Step 3
Pinch a fold of skin at your injection site (abdomen, outer thigh, or upper arm). Insert a 29 to 31 gauge needle at a 45 to 90 degree angle. Inject slowly. Hold for 5 seconds before withdrawing.
- 4Rotate injection sites
Never inject the same quadrant within two weeks. Abdomen is preferred for absorption consistency.
- 5Inject once weekly on the same day
Evening dosing is preferred so peak nausea (4 to 8 hours post-injection) occurs during sleep.
- 6Step 6
Store the reconstituted vial refrigerated at 2 to 8 degrees Celsius. Use within 4 weeks.
Retatrutide Stacking Protocols
Avoid
Both agents activate GLP-1 receptors. Combining GLP-1 agonists stacks GI side effects (nausea, vomiting, gastroparesis) with no incremental efficacy benefit: retatrutide's GLP-1 component already provides full GLP-1 agonism.
Do not combineTirzepatide is a GLP-1/GIP dual agonist. Combining with retatrutide creates redundant GLP-1 and GIP receptor activation with compounding GI risk and no clinical rationale.
Do not combineAdding a fixed-dose GLP-1 combination on top of a triple GLP-1/GIP/glucagon agonist introduces overlapping GLP-1 activity and entirely unstudied additive risk.
Do not combineRetatrutide's GLP-1 and GIP components both lower blood glucose; combining with insulin or sulfonylureas increases hypoglycemia risk, especially in type 2 diabetes. Medical supervision required.
How much does Retatrutide cost?
Typical price
$7.00 to $10.66 per mg
Middle half of 86 US prices for 10 mg vials · read Oct 31
Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.
Pricing updated 2026-04-09
Retatrutide Side Effects
Gastrointestinal events during dose escalation are the defining tolerability challenge with retatrutide. Community users often describe them as rougher than on other GLP-1 drugs, though no head-to-head trial has tested that.
In TRIUMPH-4 Phase 3 data (Lilly topline 2025), nausea occurred in 38 to 43% of participants. Diarrhea affected 33 to 35%. Constipation hit 22 to 25%. Vomiting was reported in 21%. Side effects led 12.2% on 9 mg and 18.2% on 12 mg to stop, vs 4.0% on placebo. These rates are dose-dependent and front-loaded, meaning they peak during the weeks immediately after each dose increase. Most GI events resolve within 1 to 2 weeks at a stable dose. Stepping up slowly, with 4 weeks between escalations as the Phase 3 trials do, is the standard way to limit them.
Raised resting heart rate is the second signal that deserves attention. Phase 2 trials [1] documented a dose-dependent increase in resting HR tied to glucagon receptor activation. Community users at 8 mg and above have reported palpitations and sustained HR above 90 bpm. The TRIUMPH-1 and TRIUMPH-2 abstracts report no heart rate figures, so anyone with a cardiac history should track heart rate weekly during titration. Do not escalate if resting HR stays above 100 bpm.
Dysesthesia is the newer Phase 3 signal. It means abnormal skin sensations such as tingling, burning, or numbness. In TRIUMPH-4 it showed up in 8.8% on 9 mg and 20.9% on 12 mg, vs 0.7% on placebo. TRIUMPH-1 reported 5.1 to 12.5% across the 4, 9, and 12 mg doses, vs 0.9% on placebo. Most cases were mild to moderate and resolved during treatment (Lilly topline figures; the TRIUMPH-1 NEJM abstract does not give dysesthesia rates).
TRIUMPH-2 (Lancet 2026)[13], in 1,152 adults with obesity and type 2 diabetes, flagged low blood pressure. Hypotension hit 1%, 5%, and 6% on 4, 9, and 12 mg vs under 1% on placebo. Dysesthesia ran 4 to 7% vs 1%. Gastrointestinal events were still the most frequent: diarrhea hit 27 to 34% vs 13% on placebo, and nausea 14 to 28% vs 8%. Stopping for side effects or death ran 12% on 9 mg and 8% on 12 mg, vs 4% on 4 mg and 5% on placebo. Lightheadedness on standing is worth a blood pressure check.
Post-injection fatigue, sometimes called "wipeout day," shows up consistently in community reports at doses of 8 mg or higher. Users describe pronounced fatigue lasting 12 to 24 hours after injection, particularly during the first 2 to 4 weeks at a new dose level. Scheduling the injection on a low-demand day helps.
The GLP-1 class carries an unresolved rodent thyroid C-cell tumor signal. No confirmed human thyroid cancer risk has been established for any GLP-1 agonist, but retatrutide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
Pancreatitis is a known class risk. Severe persistent abdominal pain radiating to the back warrants immediate medical attention and discontinuation.
Pregnancy is an absolute contraindication. No human pregnancy data have been published for retatrutide. Discontinue well before any planned pregnancy.
Product quality adds a layer of risk specific to investigational peptides. Retatrutide is not FDA approved; compounded versions lack standardized formulation. A Certificate of Analysis with HPLC purity data is the only check on each batch. Grey-market research chemicals carry contamination and identity risks that cannot be verified.
Common Issues & Solutions
Severe nausea 1–3 days post-injection: Extend current dose step to 6–8 weeks before escalating. Inject in the evening so peak nausea occurs during sleep. Anti-nausea medications (ondansetron, promethazine) are routinely used in clinical practice. Some community users add BPC-157 daily during titration.
Resting heart rate elevated (>90–100 bpm): Dose-dependent glucagon receptor effect seen in Phase 2. Do not escalate dose until HR normalizes. If persistent at current dose, step down one level. Avoid stimulants (caffeine, pre-workout). HR should normalize within weeks at a stable dose.
Weight loss stalling at low doses (1–2 mg): Usually incomplete titration, not a plateau: 1–2 mg are tolerability steps, not therapeutic targets. Escalate per protocol if GI symptoms allow. Stalls at therapeutic dose (8–12 mg) may reflect a new metabolic equilibrium.
Injection site reaction (redness, nodule, bruising): Normal subcutaneous response. Rotate strictly between abdomen, thigh, and upper arm quadrants: never inject the same quadrant within 2 weeks. Warm the reconstituted vial briefly in your hands before injecting.
Fatigue and "wipeout" the day after injection (at ≥8 mg): Reported in community at higher doses, particularly in the first weeks at a new dose level. Schedule injection on a low-demand day. Ensure hydration and electrolyte replacement: GI fluid losses compound fatigue. Typically resolves within 2–4 weeks at a stable dose.
Ask AI about this page
Ask AI for a second opinion on Retatrutide dosing and side effects
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- History of pancreatitis
- Pregnancy or breastfeeding
- Known hypersensitivity to retatrutide or any excipients
- Severe gastrointestinal disease (e.g., gastroparesis)
Drug Interactions
- Insulin and sulfonylureas: increased hypoglycemia risk due to combined glucose-lowering effects
- Oral medications may have delayed absorption due to slowed gastric emptying
- Levothyroxine: monitor thyroid levels as absorption timing may be altered
- Warfarin: monitor INR more frequently during initiation and dose changes
- Tirzepatide is a GLP-1/GIP dual agonist. Combining with retatrutide creates redundant GLP-1 and GIP receptor activation with compounding GI risk and no clinical rationale.
- Adding a fixed-dose GLP-1 combination on top of a triple GLP-1/GIP/glucagon agonist introduces overlapping GLP-1 activity and entirely unstudied additive risk.
Product Quality
Retatrutide is not FDA approved. The only regulated routes are clinical trials and Lilly's expanded access program (NCT07629401). No standardized formulation exists. Compounded versions lack regulatory verification of peptide purity and dosing accuracy. Grey-market research chemical sources carry additional contamination and peptide identity risks.
- 503B status does not help here: FDA says drugs compounded with retatrutide are not eligible for the 503A or 503B exemptions (warning letters, September 9, 2025)
- Only a Certificate of Analysis (CoA) with HPLC purity data confirms what a batch holds
- Require endotoxin (pyrogen) testing documentation: critical for subcutaneous injectables
- Never use grey-market research chemical powder: dosing accuracy and peptide identity cannot be verified
- Verify the pharmacy has an active state license and no FDA warning letters on file (FDA.gov enforcement database)
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Resting heart rate | Weekly during titration; monthly at stable dose | <90 bpm at rest; pause dose escalation if sustained >100 bpm; consult prescriber |
| Fasting glucose / HbA1c | Baseline, then every 3 months | Fasting glucose 70–100 mg/dL; HbA1c <5.7% (non-diabetic range) |
| Lipid panel (LDL, non-HDL, triglycerides, hsCRP) | Baseline, 12 weeks, then every 6 months | Not listed |
| Liver enzymes (ALT, AST) | Baseline, then every 3 months in first year | Not listed |
| Body weight + waist circumference | Weekly during active titration; biweekly at maintenance | Not listed |
| Blood pressure (systolic/diastolic) | Monthly | Not listed |
| Thyroid function (TSH) | Baseline; annually or if symptomatic | Not listed |
Dose-dependent resting HR increase observed in Phase 2 trials. Glucagon receptor activation raises energy expenditure and may elevate HR. The TRIUMPH-1 and TRIUMPH-2 abstracts report no heart rate figures, so check it at each dose escalation step.
Net effect is glucose-lowering (GLP-1/GIP dominant over glucagon at therapeutic doses), but monitoring is essential in diabetic patients and those on insulin or sulfonylureas where hypoglycemia risk is elevated.
Phase 3 TRIUMPH-4 showed significant reductions in non-HDL cholesterol, triglycerides, and hsCRP at 12 mg. Baseline values are needed to quantify benefit and catch any anomalous changes.
Retatrutide is under Phase 3 investigation for MASLD. Monitoring confirms therapeutic liver enzyme normalization and detects any drug-related hepatic stress.
Primary efficacy endpoint. Weekly tracking guides titration decisions and identifies early non-response.
Phase 3 showed reduction in systolic BP at 12 mg. Patients on antihypertensives may need dose adjustment as BP falls alongside weight loss.
GLP-1 class carries an unresolved rodent thyroid C-cell tumor signal. No confirmed human risk, but TSH monitoring is standard precaution for GLP-1 receptor agonists.
Retatrutide Before and After
Titration initiation. Phase 3 trials start at 2 mg; many community users start at 1 mg. Mild appetite reduction begins. GI side effects (nausea, decreased appetite) are most common early. Body adjusts to triple-receptor activation.
Appetite suppression becomes more pronounced. Early weight loss of 3-5%. GI side effects typically begin to ease as the body adapts to escalating doses.
Steady weight loss accelerates. Liver fat reduction becomes measurable. Blood sugar and lipid markers improve. Most users experience 8-12% body weight reduction.
Approaching full therapeutic dose. Clinical trials showed ~17.5% mean weight loss at 24 weeks. Significant metabolic improvements across multiple markers.
Full dose maintenance. Phase 2 trials showed up to 24.2% body weight loss at 48 weeks. Liver fat reduced by over 80% at higher doses. Weight loss rate slows as a new equilibrium is reached.
What to Expect
Weeks 1 to 4 (1 to 2 mg): Phase 3 trials start at 2 mg; many community users start at 1 mg. Either way, this is a GI adaptation step, not a therapeutic dose. Science expects minimal weight change. Community users report appetite suppression beginning within 3 to 5 days, though the intensity varies widely. Nausea, decreased appetite, and fatigue are most common here. Injection site redness happens. The body is adjusting to triple-receptor activation for the first time.
Weeks 5 to 12 (2 to 4 mg): Weight loss becomes measurable. Phase 2 data shows 5 to 8% body weight reduction beginning in this dose range. Community users report 1 to 1.5 lbs per week and describe food noise as significantly reduced. GI events generally ease as the body adapts to a stable dose. Resting heart rate may start climbing; track it weekly from this step forward. Liver fat reduction becomes detectable at 4 mg in the MASLD subgroup.
Weeks 13 to 24 (4 to 8 mg): The therapeutic range. Phase 2 showed approximately 17.5% mean weight loss at 24 weeks across the highest-dose groups. Community users call this the "sweet spot," reporting 1.5 to 2.5 lbs per week with manageable side effects. Liver fat drops sharply: 57% reduction at 4 mg and 81.4% at 8 mg in the Phase 2a MASLD trial [2]. Heart rate elevation is most prominent entering 8 mg. Post-injection fatigue may appear.
Weeks 25 to 68+ (8 to 12 mg): High-dose maintenance. Phase 2 data showed 24.2% body weight reduction at 48 weeks on 12 mg [1]. TRIUMPH-4 Phase 3 pushed that to 28.7% at 68 weeks. Liver fat reaches its lowest point by week 24. Blood pressure, non-HDL cholesterol, triglycerides, and hsCRP all improved in TRIUMPH-4. Weight loss rate slows as the body approaches a new equilibrium. Some users step down from 12 mg to 8 mg, trading modest efficacy for better tolerability. Heart rate elevations are most prominent at 12 mg but generally stabilize with sustained time at dose.
Detailed Timeline: Science vs Community
Tolerability establishment. Phase 3 trials start at 2 mg; 1 mg is a common community start. Minimal weight change expected: this is a GI adaptation step, not a therapeutic target.
Appetite suppression begins within 3–5 days in most users. Hunger reduction noticeable even at 1 mg for many, though highly variable between individuals.
Phase 2 data shows 5–8% body weight reduction beginning in this dose range. Liver fat reduction detectable at 4 mg in MASLD subgroup.
Measurable weight loss. Most users report 1–1.5 lbs/week. Cravings and food noise significantly reduced. Energy improving alongside early weight loss.
Phase 2 showed ~17.5% mean weight loss across highest-dose groups at week 24. Liver fat measurably reduced (−57% at 4 mg, −81.4% at 8 mg in MASLD Phase 2a).
Strong weight loss continues. Many users report 1.5–2.5 lbs/week. This range is commonly described as the "sweet spot": high efficacy with manageable tolerability.
Phase 2: −24.2% body weight at 48 weeks (12 mg). Phase 3 TRIUMPH-4: −28.7% at 68 weeks (12 mg). Liver fat reaches nadir by week 24. BP, non-HDL cholesterol, triglycerides, and hsCRP all improved in TRIUMPH-4.
Weight loss rate slows as a new equilibrium is approached. Metabolic labs often visibly improved. Some users reduce from 12 mg to 8 mg for better tolerability with modest efficacy trade-off.
Pharmacokinetics
Source: Phase 1 single-dose study, mean ~6 days, as reviewed in Biomolecules 2025 (PMID 40563436)
Pharmacokinetics: Active Dose Over Time
t½ = ~6 daysDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Retatrutide Legal?
Retatrutide (LY3437943) is an investigational drug. It has not received FDA approval for any indication. Eli Lilly reported Phase 3 results from TRIUMPH-4 (December 2025), TRIUMPH-1 (May 2026), and TRIUMPH-2 and TRIUMPH-3 (July 2026). Lilly plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027.
Outside clinical trials, Lilly runs a pre-approval expanded access program (ClinicalTrials.gov NCT07629401, first posted June 5, 2026, status Available). It is open to adults who can't join a retatrutide trial and have a BMI of 35 or higher despite the highest available dose of weight management therapy. They also need two or more serious obesity-related complications. Retatrutide does not appear in FDA's 503A bulk substance categories (updated May 14, 2026), and no FDA-approved retatrutide product exists. FDA warning letters dated September 9, 2025 say drugs compounded with retatrutide are not eligible for the 503A or 503B exemptions. Products sold as compounded retatrutide are not the investigational drug used in Lilly's trials, and no regulator has checked their purity or dose.
For athletes subject to anti-doping testing, WADA's 2026 Prohibited List does not name retatrutide or any other GLP-1 receptor agonist. Retatrutide has no regulatory approval, though, so it may fall under section S0 (non-approved substances), which WADA prohibits in and out of competition. Check with your anti-doping organization before use.
All content on this page is for educational and informational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any investigational compound.
Evidence grade: Phase 3 trial (Peptide Evidence Gap, October 2026)
Who Should Consider Retatrutide
- Adults with BMI ≥30 (or ≥27 with weight-related comorbidity)
- Individuals seeking maximum weight loss beyond dual-agonist options
- Adults with metabolic dysfunction-associated steatotic liver disease (MASLD)
- Patients with obesity-related comorbidities (type 2 diabetes, dyslipidemia)
- Adults who have plateaued on GLP-1 or dual-agonist therapy
Related Peptides
What Changed for Retatrutide
- Safety
Corrected Oct 14, 2026: retatrutide side effects now give TRIUMPH-2 stop rates, 8 to 12% on 9 and 12 mg vs 5% on placebo, per The Lancet.
Before: No discontinuation rates; said Phase 3 data suggest the heart rate rise is manageable; said no reproductive toxicity data exist After: TRIUMPH-2 stop rates (12% on 9 mg, 8% on 12 mg vs 5%) and TRIUMPH-4 topline rates added; no heart rate figures in the TRIUMPH-1 and -2 abstracts; no published pregnancy data
What this does not mean: No new signal. The page also drops a claim that Phase 3 showed the heart rate rise is manageable; the TRIUMPH-1 and TRIUMPH-2 abstracts give no heart rate figures.
Source: Lancet 2026, Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Evidence
TRIUMPH-2 reported 18.8% weight loss on retatrutide 12 mg vs 5.1% on placebo at 80 weeks in type 2 diabetes, published Sep 29, 2026, per The Lancet.
What this does not mean: Treatment-regimen figures in 1,152 adults with obesity and type 2 diabetes. Lilly's July 2026 topline of 20.8% used the efficacy estimand.
Source: Lancet 2026, Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
TRIUMPH-2 found more hypotension (up to 6% vs under 1%) and dysesthesia (up to 7% vs 1%) on retatrutide, published Sep 29, 2026, per The Lancet.
Before: No hypotension text; dysesthesia cited from Lilly toplines only, with TRIUMPH-1 labeled not yet peer-reviewed. After: TRIUMPH-2 (Lancet 2026): hypotension 1 to 6% vs under 1% on placebo; dysesthesia 4 to 7% vs 1%; diarrhea and nausea led.
What this does not mean: Rates rose with dose (hypotension 1%, 5%, 6% on 4, 9, 12 mg). The trial was not designed to test blood pressure safety.
Source: Lancet 2026, Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Evidence
TRIUMPH-1 reported 25.0% weight loss on retatrutide 12 mg vs 3.9% on placebo at 80 weeks, published Sep 29, 2026, per NEJM.
What this does not mean: These are treatment-regimen figures that count everyone randomized. Lilly's 28.3% topline used the efficacy estimand. Retatrutide has no FDA approval.
Source: N Engl J Med 2026, Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Evidence
ApoB, a heart-risk marker, fell 24.2% on retatrutide 12 mg vs 6.8% on placebo in phase 2, published Aug 17, 2026, per Diabetes Obes Metab.
What this does not mean: Post hoc and Lilly-funded. The 24.2% came at 48 weeks in people without type 2 diabetes. In type 2 diabetes at 36 weeks, apoB fell 21.4% (8 mg) and 17.7% (12 mg) vs a 0.2% rise on placebo. Heart outcomes are unknown.
Source: Diabetes Obes Metab 2026, Retatrutide-associated improvements in cardiovascular risk biomarkers in adults with obesity with or without type 2 diabetes (post hoc, two phase 2 trials) (opens in a new tab) · Archived snapshot (opens in a new tab)
- Evidence
Lilly posted a pre-approval expanded access program for retatrutide on ClinicalTrials.gov on Jun 5, 2026, per NCT07629401.
What this does not mean: Expanded access is not an FDA approval. It is limited to adults with severe obesity and serious complications who cannot join a trial.
Source: ClinicalTrials.gov NCT07629401, Pre-approval Expanded Access of Retatrutide (LY3437943) (opens in a new tab) · Saved copy
- Regulatory
FDA warning letters dated Sep 9, 2025 say drugs compounded with retatrutide are not eligible for the 503A or 503B exemptions, per FDA.
What this does not mean: It is not an FDA safety finding about retatrutide itself. It concerns compounded products; Lilly's trial drug and expanded access program are separate.
Source: FDA warning letter MARCS-CMS 715506, Sep 9, 2025 (compounded retatrutide) (opens in a new tab) · Saved copy
Dates to watch
- Company-stated plan
Eli Lilly plans to submit a Biologics License Application for retatrutide to FDA in the first quarter of 2027, per Lilly.
What this does not mean: A planned filing is not an approval. Company timelines can slip, and FDA review starts only after a filing is accepted.
- Trial primary completion, estimated
TRIUMPH-6, a Phase 3 trial of retatrutide for keeping lost weight off, has an estimated primary completion month, per ClinicalTrials.gov.
What this does not mean: Primary completion is when the last participant gives data for the main outcome, not when results come out. Estimated dates often move.
Peptide Schedule Research TeamReviewed Sep 24, 202625 Citations
References
- [1]Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (NEJM 2023) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: Phase 2a Trial (Nature Medicine 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Retatrutide for People with Type 2 Diabetes: A Phase 2 Trial (Lancet 2023) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Retatrutide: A Game Changer in Obesity Pharmacotherapy (Biomolecules 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Efficacy and Safety of Retatrutide: Systematic Review and Meta-Analysis of RCTs (Proc Baylor Univ Med Ctr 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]Retatrutide for Obesity, OSA and Knee OA: Rationale and Design of the TRIUMPH Phase 3 Trials (Diabetes Obes Metab 2026) (opens in a new tab)PubMed (opens in a new tab)Clinical Trial
- [7]Retatrutide in Type 2 Diabetes Mellitus and Obesity: An Overview (Expert Rev Clin Pharmacol 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [8]Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: Network Meta-Analysis (Endocrinol Diabetes Metab 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [9]TRIUMPH-1: Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity: TRIUMPH-1 Phase 3 (NEJM 2026) (opens in a new tab)(n=2,339)PubMed (opens in a new tab)PubMed
- [10]TRIUMPH-4: Lilly topline, December 11 2025(n=445)
- [11]TRIUMPH-3: Lilly topline, July 23 2026, not yet peer-reviewed
- [12]TRANSCEND-T2D-1: Efficacy and safety of retatrutide in T2D (TRANSCEND-T2D-1): phase 3 trial (Lancet 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [13]TRIUMPH-2: Retatrutide in adults with obesity and type 2 diabetes: TRIUMPH-2 Phase 3 (Lancet 2026) (opens in a new tab)(n=1,152)PubMed (opens in a new tab)PubMed
Additional References
- The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying (Diabetes Obes Metab 2023) (opens in a new tab)PubMed 37311727PubMed
- Phase 2 obesity trial of LY3437943 (NCT04881760) (opens in a new tab)Clinical Trial
- TRIUMPH-6: retatrutide for maintenance of weight reduction (NCT06859268) (opens in a new tab)Clinical Trial
- Efficacy and Safety of Retatrutide in Diabetes and/or Obesity with Chronic Kidney Disease (Maedica 2025) (opens in a new tab)PubMed 41537067PubMed
- Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: Systematic Review and Meta-Analysis (Cardiol Rev 2026) (opens in a new tab)PubMed 41711462PubMed
- Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models (Obesity 2026) (opens in a new tab)PubMed 41741376PubMed
- Effects of retatrutide on body composition in T2D: DXA substudy (Lancet Diabetes Endocrinol 2025) (opens in a new tab)PubMed 40609566PubMed
- GLP-1, dual agonists, and retatrutide for weight loss: Bayesian NMA of 29,506 patients (Obesity 2025) (opens in a new tab)PubMed 40685589PubMed
- Tirzepatide, retatrutide, and semaglutide for weight loss in obese individuals without diabetes (Acad Emerg Med 2025) (opens in a new tab)PubMed 40583149PubMed
- Triple agonism based therapies for obesity (Curr Cardiovasc Risk Rep 2025) (opens in a new tab)PubMed 40741227PubMed
- Once-weekly subcutaneous retatrutide on weight and metabolic markers: systematic review and meta-analysis (Metabolism Open 2024) (opens in a new tab)PubMed 39318607PubMed
- FDA warning letter MARCS-CMS 715506, September 9, 2025: compounded retatrutide is not eligible for the 503A or 503B exemptions (opens in a new tab)Review
Related Resources
Related Tools
Further Reading
Storage & Stability
Frequently Asked Questions
How popular is Retatrutide?
Hot. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
132 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Very high search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.